Digi Expands IoT Solutions for Medical, Smart Energy and Industrial Sectors with Newest Addition to the MP1 Family of System-On-Modules
13.3.2023 11:00:00 EET | Business Wire | Press release
Digi International (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) solutions, connectivity products and services, and an ST Authorized Partner, today unveiled Digi ConnectCore® MP13, the newest member of its Digi ConnectCore® MP1 family of system-on-modules (SOMs) designed for longevity, scalability and demanding product lifecycles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005132/en/
Digi ConnectCore MP13 System-on-Module unveiled at Embedded World 2023 (Graphic: Business Wire)
A compact, wireless and secure system-on-module based on the STMicroelectronics STM32MP133C MPU, Digi ConnectCore MP13 is among the industry’s smallest SOMs with pre-certified Wi-Fi 5 and Bluetooth® 5.2. This solution delivers cost-effective, flexible and reliable connectivity for original equipment manufacturers (OEMs) looking to reduce risk and product development efforts, while accelerating overall time to market of applications for the medical, smart energy and industrial sectors.
Complete with embedded security framework, Digi TrustFence®, and Digi Embedded Yocto Linux® software support, Digi ConnectCore MP13 SOMs eliminate implementation barriers and offer exceptional design flexibility for both complex and simple applications thanks to the unique and compact Digi SMTplus® surface-mount form factor (29x29 mm) — making them ideal for medical devices, industrial gateways, environmental test equipment, renewable-energy controllers and EV charging stations.
“We are delighted to expand the Digi ConnectCore MP1 family of SOMs and continue our commitment to providing off-the-shelf, wireless-enabled solutions suitable for a broad range of applications,” said Andreas Burghart, Senior Product Manager at Digi. “Designed for longevity, scalability and demanding 10+ year product lifecycles, Digi ConnectCore MP13 is a well-suited addition to our complete ecosystem of hardware, software and services that help manufacturers successfully develop and maintain connected products.”
Digi ConnectCore MP1 SOMs are distinct from other SOMs in that they offer comprehensive, fully-integrated solutions, which include a range of development tools, design support, wireless connectivity options, software and security features. These solutions include access to Digi ConnectCore Cloud Services and Digi ConnectCore Security Services, which aid in streamlining deployment, device management and ongoing maintenance across the product's entire lifecycle.
Digi ConnectCore MP13 Features
- STM32MP13x, single Cortex-A7 @ 650 MHz
- Pre-certified Wi-Fi 5 802.11a/b/g/n/ac + Bluetooth 5.2 (including DLE) option
- Up to 1 GB SLC NAND flash, up to 1 GB DDR3
- Unique ultra-low power and wake-up state management
- Dual 10/100/1000 Ethernet connectivity
- Fully validated embedded Linux software platform (Digi Embedded Yocto)
- Digi TrustFence® embedded security framework — ready-to-use security features
- Off-the-shelf development board and low-cost gateway reference design
- Industrial reliability and operating temperature with leading hardware warranty
“With the launch of Digi ConnectCore MP13, Digi has created pin-compatible family of SOMs to support the ST Microelectronics STM32MP1 microprocessors,” said Dan Kobylarz, Senior Director of Engineering, OEM Solutions Group at Digi. “The ConnectCore MP13 is ideal for the rapid development of cost-effective gateways for Smart City and Energy applications, while the ConnectCore MP15 supports connected devices with HMI requirements. With the ConnectCore MP1 SOM family, a customer gets the best of both worlds.”
For more information, visit https://www.digi.com/products/embedded-systems/digi-connectcore/system-on-modules/digi-connectcore-mp1.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit https://www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005132/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 05:00:00 EEST | Press release
Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated over the three years through 2028. The amount to be awarded to Helical Fusion will be announced following the formal grant
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release
ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release
BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom